# A single dose of quadrivalent HPV vaccine is highly effective against HPV genotypes 16 and 18 detection in young pregnant women eight years following vaccination: an retrospective cohort study in Fiji

Source: https://onco.cc/key-papers/paper-reyburn-single-dose-hpv-fiji-lanwpc-2023/  
OnCo record `paper-reyburn-single-dose-hpv-fiji-lanwpc-2023` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Eight years after Fiji's 2008 and 2009 HPV vaccination campaign, a single dose of the quadrivalent vaccine was 81% effective against HPV 16 and 18 in 822 young pregnant women.

## Summary

In 2008 and 2009 Fiji vaccinated more than 30,000 girls aged 9 to 12 with the quadrivalent HPV vaccine; coverage for at least one dose was over 60%, with 14% receiving one dose only, 13% two and 35% three. This retrospective cohort study, run from 2015 to 2019, enrolled pregnant women aged 23 or under who had been eligible for the vaccine and whose vaccination status was confirmed, a median of eight years after vaccination. It was funded by the Bill and Melinda Gates Foundation and the Australian Government.

## Fields

- Kind: Key paper
- Last checked: 2026-11-16
- Journal: The Lancet Regional Health. Western Pacific
- Year: 2023
- DOI: 10.1016/j.lanwpc.2023.100798
- Authors: Reyburn R, Tuivaga E, Ratu T, et al.
- Findings: HPV 16 or 18 was detected in 13.3% (50 of 376) of unvaccinated women, 2.5% (4 of 158) after one dose, 0% (0 of 99) after two and 1.6% (3 of 189) after three.; Adjusted vaccine effectiveness against HPV 16 and 18 was 81% for one dose (95% CI 48 to 93), 100% for two and 89% for three (95% CI 64 to 96).; Detection of non-vaccine high-risk types was similar across the groups (33.2% to 40.4%).
- What it means: One dose of HPV vaccine gave lasting protection against the two types that cause most cervical cancers, in a Pacific island setting.
- Caveats: Restricted to pregnant women, because of the cultural sensitivity of asking about sexual behaviour in Fiji.; Retrospective, and it measured HPV infection, not cervical disease.

## Sources

- DOI: https://doi.org/10.1016/j.lanwpc.2023.100798
- PubMed: https://pubmed.ncbi.nlm.nih.gov/37359996/

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- technologies: [HPV & HBV vaccination](https://onco.cc/technologies/hpv-vaccine/)
- institutions: [Ministry of Health and Medical Services, Fiji](https://onco.cc/institutions/fiji-ministry-of-health/)

---
JSON: https://onco.cc/api/v1/entities/paper-reyburn-single-dose-hpv-fiji-lanwpc-2023.json